Girolami et al., 1980 - Google Patents
Chromogenic Substrate (S-2238) Prothrombin Assay in Prothrombin Deficiencies and Abnormalities. Lack of Identity with Clotting Assays in Congenital …Girolami et al., 1980
- Document ID
- 8322368489308275253
- Author
- Girolami A
- Patrassi G
- Toffanin F
- Saggin L
- Publication year
- Publication venue
- American Journal of Clinical Pathology
External Links
Snippet
Prothrombin was assayed using chromogenic substrate S-2238 for patients who were being treated with coumarin, for patients who had liver disease, and for patients who had congenital hypoprothrombinemias and dysprothrombinemias. In coumarin therapy and in …
- 102100015239 F2 0 title abstract description 50
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Griffin et al. | Deficiency of protein C in congenital thrombotic disease. | |
Bertina | Hereditary protein S deficiency | |
Massicotte et al. | Enhanced thrombin regulation during warfarin therapy in children compared to adults | |
Al-Mondhiry et al. | Fibrinogen"" New York"--an abnormal fibrinogen associated with thromboembolism: functional evaluation | |
DK171086B1 (en) | Method for photometric determination of protein C and / or protein S activity | |
DE69022425T2 (en) | Method for determining the functional effect of free Protein S or Protein C in a plasma sample. | |
Maruyama et al. | Studies on blood coagulation and fibrinolysis in patients bitten by Bothrops jararaca (jararaca) | |
Colwell et al. | Identification of a monoclonal thrombin inhibitor associated with multiple myeloma and a severe bleeding disorder | |
US5705198A (en) | Test for lupus anticoagulant | |
Soff et al. | Familial multiple coagulation factor deficiencies | |
CONLON et al. | Telangiectasia and von Willebrand's disease in two families | |
US4287180A (en) | Method for treating blood clotting factor inhibitors | |
Girolami et al. | Chromogenic Substrate (S-2238) Prothrombin Assay in Prothrombin Deficiencies and Abnormalities. Lack of Identity with Clotting Assays in Congenital Dysprothrombinemias. | |
Briët et al. | Molecular variant of factor VII | |
Hedner et al. | Inhibition of activated haceman factor (factor XIIa) by an inhibitor of the plasminogen activation (PA inhibitor) | |
EP0044343A1 (en) | Prothrombin-containing therapeutic compositions and methods of producing enzymatically active blood clotting factors from prothrombin-containing blood fractions. | |
Zucker et al. | IgM Inhibitors of the Contact Activation Phase of Coagulation in Chlorpromazine‐Treated Patients | |
Girolami et al. | Factor X assays using chromogenic substrate S-2222 | |
US20090221012A1 (en) | Method for Detecting Procoagulant Phospholipid | |
Sala et al. | Dysfunctional activated protein C (PC Cadiz) in a patient with thrombotic disease | |
US4663164A (en) | Aqueous compositions for treating blood clotting factor inhibitors | |
Harbaugh et al. | Antithrombin and antithromboplastin activity accompanying IgG myeloma: Report of a case with a severe bleeding tendency | |
Davey et al. | Gamma globulin inhibition of fibrin clot formation | |
Hellstern | Composition of plasma | |
Palmer et al. | Inhibition of the cold activation of factor VII and the prothrombin time |